Skip to main content
Hauptrubriken
CME Facharzt-Training Webinare Zeitschriften Bücher e.Medpedia Podcast
Service
Jobbörse Info & Hilfe
Fachgebiete
Anästhesiologie Allgemeinmedizin Arbeitsmedizin Augenheilkunde Chirurgie Dermatologie Gynäkologie und Geburtshilfe HNO Innere Medizin Kardiologie Neurologie Onkologie und Hämatologie Orthopädie und Unfallchirurgie Pädiatrie Pathologie Psychiatrie Radiologie Rechtsmedizin Urologie Zahnmedizin
Themen
Typ-2-Diabetes und Adipositas Klimawandel und Gesundheit Neues aus dem Markt COVID-19 Praxis und Beruf Seltene Erkrankungen GOÄ & EBM Panorama
Sammlungen
Kasuistiken Algorithmen & Infografiken Blickdiagnosen Arthropedia FlapFinder (für Dermatochirurgen) Videos Kongressberichterstattung Medizin für Apothekerinnen und Apotheker Für Ärztinnen und Ärzte in Weiterbildung Für Medizinstudierende

Live-Webinar "Urologie und Sexualmedizin in der Praxis"

Häufige urologisch-sexualmedizinische Themen in der Praxis sind das Thema des MMW-Webinars am 5. Juni von 17.30 bis 19 Uhr. Konkret geht es um die Frage, wann bei Harnwegsinfektionen auf Antibiotika verzichtet werden kann, und um ein Update zur Therapie von Libido- und Potenzstörungen des Mannes. Der dritte Vortrag behandelt sexuell übertragbare Krankheiten. Stellen Sie Ihre Fragen an die Experten und sammeln Sie 2 CME-Punkte. Jetzt gleich anmelden!
Erweiterte Suche
Anmelden
nach oben
Immunologic Research
Erschienen in: Immunologic Research 1-3/2013

01.12.2013 | Immunology & Microbiology in Miami

B-lymphocyte tolerance and effector function in immunity and autoimmunity

verfasst von: Wasif N. Khan, Jacqueline A. Wright, Eden Kleiman, Justin C. Boucher, Iris Castro, Emily S. Clark

Erschienen in: Immunologic Research | Ausgabe 1-3/2013

Einloggen, um Zugang zu erhalten

Abstract

B-lymphocytes are integral to host defense against microbial pathogens and are associated with many autoimmune diseases. The B-cell receptor implements B-cell self-tolerance based on the antigen specificity, and B-cell-activating factor receptor (BAFF-R) imposes homeostatic control. While shaping the repertoire, the immune tolerance process also culls mature B cells into distinct populations. The activation response of B cells is tailored to the type of pathogen attack and is facilitated by T-cell help via CD40/CD40L interaction and/or innate cell help via toll-like receptors in conjunction with BAFF receptors and ligands. Activated effector B cells not only produce antibodies, but also produce a variety of cytokines to enhance and suppress the immune response. Not surprisingly, B cells play multiple roles in both humoral and cellular immune responses during infection and autoimmune pathogenesis. Here, we discuss how gene expression and signaling networks regulate peripheral B-cell tolerance, B-cell effector functions and emerging therapies targeting B-cell signaling in autoimmune diseases.
Literatur
1.
Allman D, Pillai S. Peripheral B cell subsets. Curr Opin Immunol. 2008;20:149–57.
2.
3.
4.
Su TT, Rawlings DJ. Transitional B lymphocyte subsets operate as distinct checkpoints in murine splenic B cell development. J Immunol. 2002;168(5):2101–10.PubMedCrossRef
5.
6.
Allman DM, Ferguson SE, Cancro MP. Peripheral B cell maturation. I. Immature peripheral B cells in adults are heat-stable antigen and exhibit unique signaling characteristics. J Immunol. 1992;149(8):2533–40.PubMed
7.
Allman DM, Ferguson SE, Lentz VM, Cancro MP. Peripheral B cell maturation. II. Heat-stable antigen(hi) splenic B cells are an immature developmental intermediate in the production of long-lived marrow-derived B cells. J Immunol. 1993;151(9):4431–44.PubMed
8.
9.
Su TT, Guo B, Wei B, Braun J, Rawlings DJ. Signaling in transitional type 2 B cells is critical for peripheral B-cell development. Immunol Rev. 2004;197:161–78.PubMedCrossRef
10.
Goodnow CC, Crosbie J, Adelstein S, Lavoie TB, Smith-Gill SJ, Brink RA, et al. Altered immunoglobulin expression and functional silencing of self- reactive B lymphocytes in transgenic mice. Nature. 1988;334(6184):676–82.PubMedCrossRef
11.
Hartley SB, Cooke MP, Fulcher DA, Harris AW, Cory S, Basten A, et al. Elimination of self-reactive B lymphocytes proceeds in two stages: arrested development and cell death. Cell. 1993;72(3):325–35.PubMedCrossRef
12.
Goodnow CC, Cyster JG, Hartley SB, Bell SE, Cooke MP, Healy JI, et al. Self-tolerance checkpoints in B lymphocyte development. Adv Immunol. 1995;59:279–368.PubMedCrossRef
13.
Khan WN, Shinners NP, Castro I, Hoek KL. BAFF receptor regulation of peripheral B lymphocyte survival and development. In: Cancro MP, editor. BLyS ligands and receptors. Humana Press; 2009. p. 19–41.
14.
Meyer-Bahlburg A, Andrews SF, Yu KO, Porcelli SA, Rawlings DJ. Characterization of a late transitional B cell population highly sensitive to BAFF-mediated homeostatic proliferation. J Exp Med. 2008;205(1):155–68.PubMedCentralPubMedCrossRef
15.
16.
17.
18.
19.
Kraus M, Alimzhanov MB, Rajewsky N, Rajewsky K. Survival of resting mature B lymphocytes depends on BCR signaling via the Igalpha/beta heterodimer. Cell. 2004;117(6):787–800.PubMedCrossRef
20.
Lam KP, Rajewsky K. Rapid elimination of mature autoreactive B cells demonstrated by Cre-induced change in B cell antigen receptor specificity in vivo. Proc Natl Acad Sci USA. 1998;95(22):13171–5.PubMedCentralPubMedCrossRef
21.
22.
Reth M, Wienands J. Initiation and processing of signals from the B cell antigen receptor. Annu Rev Immunol. 1997;15:453–79.PubMedCrossRef
23.
24.
25.
26.
Fruman DA. Towards an understanding of isoform specificity in phosphoinositide 3-kinase signalling in lymphocytes. Biochem Soc Trans. 2004;32(Pt 2):315–9.PubMedCrossRef
27.
Khan WN, Alt FW, Gerstein RM, Malynn BA, Larsson I, Rathbun G, et al. Defective B cell development and function in Btk-deficient mice. Immunity. 1995;3(3):283–99.PubMedCrossRef
28.
Rawlings DJ, Saffran DC, Tsukada S, Largaespada DA, Grimaldi JC, Cohen L, et al. Mutation of unique region of Bruton’s tyrosine kinase in immunodeficient XID mice. Science. 1993;261(5119):358–61.PubMedCrossRef
29.
Thomas JD, Sideras P, Smith CI, Vorechovsky I, Chapman V, Paul WE. Colocalization of X-linked agammaglobulinemia and X-linked immunodeficiency genes. Science. 1993;261(5119):355–8.PubMedCrossRef
30.
Humphries LA, Dangelmaier C, Sommer K, Kipp K, Kato RM, Griffith N, et al. Tec kinases mediate sustained calcium influx via site-specific tyrosine phosphorylation of the phospholipase Cgamma Src homology 2-Src homology 3 linker. J Biol Chem. 2004;279(36):37651–61.PubMedCrossRef
31.
Kim YJ, Sekiya F, Poulin B, Bae YS, Rhee SG. Mechanism of B-cell receptor-induced phosphorylation and activation of phospholipase C-gamma2. Mol Cell Biol. 2004;24(22):9986–99.PubMedCentralPubMedCrossRef
32.
Antony P, Petro JB, Carlesso G, Shinners NP, Lowe J, Khan WN. B-cell antigen receptor activates transcription factors NFAT (nuclear factor of activated T-cells) and NF-kappaB (nuclear factor kappaB) via a mechanism that involves diacylglycerol. Biochem Soc Trans. 2004;32(Pt 1):113–5. doi:10.​1042/​BST0320113.PubMedCrossRef
33.
Bajpai UD, Zhang K, Teutsch M, Sen R, Wortis HH. Bruton’s tyrosine kinase links the B cell receptor to nuclear factor kappaB activation. J Exp Med. 2000;191(10):1735–44.PubMedCentralPubMedCrossRef
34.
Petro JB, Castro I, Lowe J, Khan WN. Bruton’s tyrosine kinase targets NF-kappaB to the bcl-x promoter via a mechanism involving phospholipase C-gamma2 following B cell antigen receptor engagement. FEBS Lett. 2002;532(1–2):57–60.PubMedCrossRef
35.
Petro JB, Khan WN. Phospholipase C-gamma 2 couples Bruton’s tyrosine kinase to the NF-kappa B signaling pathway in B lymphocytes. J Biol Chem. 2001;276(3):1715–9.PubMedCrossRef
36.
Petro JB, Rahman SM, Ballard DW, Khan WN. Bruton’s tyrosine kinase is required for activation of IkappaB kinase and nuclear factor kappaB in response to B cell receptor engagement. J Exp Med. 2000;191(10):1745–54.PubMedCentralPubMedCrossRef
37.
Su TT, Guo B, Kawakami Y, Sommer K, Chae K, Humphries LA, et al. PKC-beta controls I kappa B kinase lipid raft recruitment and activation in response to BCR signaling. Nat Immunol. 2002;3(8):780–6.PubMed
38.
Hara H, Wada T, Bakal C, Kozieradzki I, Suzuki S, Suzuki N, et al. The MAGUK family protein CARD11 is essential for lymphocyte activation. Immunity. 2003;18(6):763–75.PubMedCrossRef
39.
Matsumoto R, Wang D, Blonska M, Li H, Kobayashi M, Pappu B, et al. Phosphorylation of CARMA1 plays a critical role in T Cell receptor-mediated NF-kappaB activation. Immunity. 2005;23(6):575–85.PubMedCrossRef
40.
Ruland J, Duncan GS, Elia A, del Barco Barrantes I, Nguyen L, Plyte S, et al. Bcl10 is a positive regulator of antigen receptor-induced activation of NF-kappaB and neural tube closure. Cell. 2001;104(1):33–42.PubMedCrossRef
41.
Shinohara H, Yasuda T, Aiba Y, Sanjo H, Hamadate M, Watarai H, et al. PKC beta regulates BCR-mediated IKK activation by facilitating the interaction between TAK1 and CARMA1. J Exp Med. 2005;202(10):1423–31.PubMedCentralPubMedCrossRef
42.
Sommer K, Guo B, Pomerantz JL, Bandaranayake AD, Moreno-Garcia ME, Ovechkina YL, et al. Phosphorylation of the CARMA1 linker controls NF-kappaB activation. Immunity. 2005;23(6):561–74.PubMedCrossRef
43.
Zhou H, Wertz I, O’Rourke K, Ultsch M, Seshagiri S, Eby M, et al. Bcl10 activates the NF-kappaB pathway through ubiquitination of NEMO. Nature. 2004;427(6970):167–71.PubMedCrossRef
44.
Li ZW, Omori SA, Labuda T, Karin M, Rickert RC. IKK beta is required for peripheral B cell survival and proliferation. J Immunol. 2003;170(9):4630–7.PubMedCrossRef
45.
Pasparakis M, Schmidt-Supprian M, Rajewsky K. IkappaB kinase signaling is essential for maintenance of mature B cells. J Exp Med. 2002;196(6):743–52.PubMedCentralPubMedCrossRef
46.
Xue L, Morris SW, Orihuela C, Tuomanen E, Cui X, Wen R, et al. Defective development and function of Bcl10-deficient follicular, marginal zone and B1 B cells. Nat Immunol. 2003;4(9):857–65.PubMedCrossRef
47.
Rawlings DJ, Sommer K, Moreno-Garcia ME. The CARMA1 signalosome links the signalling machinery of adaptive and innate immunity in lymphocytes. Nat Rev Immunol. 2006;6(11):799–812.PubMedCrossRef
48.
Petro JB, Gerstein RM, Lowe J, Carter RS, Shinners N, Khan WN. Transitional type 1 and 2 B lymphocyte subsets are differentially responsive to antigen receptor signaling. J Biol Chem. 2002;277(50):48009–19.PubMedCrossRef
49.
50.
51.
Coughlin JJ, Stang SL, Dower NA, Stone JC. RasGRP1 and RasGRP3 regulate B cell proliferation by facilitating B cell receptor-Ras signaling. J Immunol. 2005;175(11):7179–84.PubMedCrossRef
52.
Grandien A, Modigliani Y, Freitas A, Andersson J, Coutinho A. Positive and negative selection of antibody repertoires during B-cell differentiation. Immunol Rev. 1994;137:53–89.PubMedCrossRef
53.
Wardemann H, Yurasov S, Schaefer A, Young JW, Meffre E, Nussenzweig MC. Predominant autoantibody production by early human B cell precursors. Science. 2003;301(5638):1374–7.PubMedCrossRef
54.
55.
Nossal GJ, Pike BL. Clonal anergy: persistence in tolerant mice of antigen-binding B lymphocytes incapable of responding to antigen or mitogen. Proc Natl Acad Sci USA. 1980;77(3):1602–6.PubMedCentralPubMedCrossRef
56.
57.
58.
Loder F, Mutschler B, Ray RJ, Paige CJ, Sideras P, Torres R, et al. B cell development in the spleen takes place in discrete steps and is determined by the quality of B cell receptor-derived signals. J Exp Med. 1999;190(1):75–89.PubMedCentralPubMedCrossRef
59.
Nussenzweig MC, Meffre E, Young JW, Schaefer A, Yurasov S, Wardemann H. Predominant autoantibody production by early human B cell precursors. Science. 2003;301:1374–7.PubMedCrossRef
60.
61.
62.
Yurasov S, Wardemann H, Hammersen J, Tsuiji M, Meffre E, Pascual V, et al. Defective B cell tolerance checkpoints in systemic lupus erythematosus. J Exp Med. 2005;201(5):703–11.PubMedCentralPubMedCrossRef
63.
Kench JA, Russell DM, Nemazee D. Efficient peripheral clonal elimination of B lymphocytes in MRL/lpr mice bearing autoantibody transgenes. J Exp Med. 1998;188(5):909–17.PubMedCentralPubMedCrossRef
64.
65.
Allman D, Lindsley RC, DeMuth W, Rudd K, Shinton SA, Hardy RR. Resolution of three nonproliferative immature splenic B cell subsets reveals multiple selection points during peripheral B cell maturation. J Immunol. 2001;167(12):6834–40.PubMedCrossRef
66.
Hoek KL, Antony P, Lowe J, Shinners N, Sarmah B, Wente SR, et al. Transitional B cell fate is associated with developmental stage-specific regulation of diacylglycerol and calcium signaling upon B cell receptor engagement. J Immunol. 2006;177(8):5405–13.PubMedCrossRef
67.
Henderson RB, Grys K, Vehlow A, de Bettignies C, Zachacz A, Henley T, et al. A novel Rac-dependent checkpoint in B cell development controls entry into the splenic white pulp and cell survival. J Exp Med. 2010;207(4):837–53.PubMedCentralPubMedCrossRef
68.
69.
70.
71.
72.
73.
Gauld SB, Benschop RJ, Merrell KT, Cambier JC. Maintenance of B cell anergy requires constant antigen receptor occupancy and signaling. Nat Immunol. 2005;6(11):1160–7. doi:10.​1038/​ni1256.PubMedCrossRef
74.
Merrell KT, Benschop RJ, Gauld SB, Aviszus K, Decote-Ricardo D, Wysocki LJ, et al. Identification of anergic B cells within a wild-type repertoire. Immunity. 2006;25(6):953–62.PubMedCrossRef
75.
76.
77.
78.
Kiefer K, Nakajima PB, Oshinsky J, Seeholzer SH, Radic M, Bosma GC, et al. Antigen receptor editing in anti-DNA transitional B cells deficient for surface IgM. J Immunol. 2008;180(9):6094–106.PubMedCrossRef
79.
Wang H, Feng J, Qi CF, Li Z, Morse HC 3rd, Clarke SH. Transitional B cells lose their ability to receptor edit but retain their potential for positive and negative selection. J Immunol. 2007;179(11):7544–52.PubMedCrossRef
80.
Behrens TW, Rajewsky K, Schlissel MS. Basal immunoglobulin signaling actively maintains developmental stage in immature B cells. PLoS One. 2005;3(3):463–75.
81.
Monroe RJ, Seidl KJ, Gaertner F, Han S, Chen F, Sekiguchi J, et al. RAG2:GFP knockin mice reveal novel aspects of RAG2 expression in primary and peripheral lymphoid tissues. Immunity. 1999;11(2):201–12.PubMedCrossRef
82.
Castro I, Wright JA, Damdinsuren B, Hoek KL, Carlesso G, Shinners NP, et al. B cell receptor-mediated sustained c-Rel activation facilitates late transitional B cell survival through control of B cell activating factor receptor and NF-kappaB2. J Immunol. 2009;182(12):7729–37. doi:10.​4049/​jimmunol.​0803281.PubMedCentralPubMedCrossRef
83.
Cheng S, Hsia CY, Feng B, Liou ML, Fang X, Pandolfi PP, et al. BCR-mediated apoptosis associated with negative selection of immature B cells is selectively dependent on Pten. Cell Res. 2009;19(2):196–207.PubMedCrossRef
84.
85.
86.
Enders A, Bouillet P, Puthalakath H, Xu Y, Tarlinton DM, Strasser A. Loss of the pro-apoptotic BH3-only Bcl-2 family member Bim inhibits BCR stimulation-induced apoptosis and deletion of autoreactive B cells. J Exp Med. 2003;198(7):1119–26.PubMedCentralPubMedCrossRef
87.
88.
Wang H, Clarke SH. Evidence for a ligand-mediated positive selection signal in differentiation to a mature B cell. J Immunol. 2003;171(12):6381–8.PubMedCrossRef
89.
Batten M, Groom J, Cachero TG, Qian F, Schneider P, Tschopp J, et al. BAFF mediates survival of peripheral immature B lymphocytes. J Exp Med. 2000;192(10):1453–66.PubMedCentralPubMedCrossRef
90.
91.
Huang X, Di Liberto M, Cunningham AF, Kang L, Cheng S, Ely S, et al. Homeostatic cell-cycle control by BLyS: induction of cell-cycle entry but not G1/S transition in opposition to p18INK4c and p27Kip1. Proc Natl Acad Sci USA. 2004;101(51):17789–94.PubMedCentralPubMedCrossRef
92.
Schiemann B, Gommerman JL, Vora K, Cachero TG, Shulga-Morskaya S, Dobles M, et al. An essential role for BAFF in the normal development of B cells through a BCMA-independent pathway. Science. 2001;293(5537):2111–4.PubMedCrossRef
93.
94.
95.
96.
Groom JR, Fletcher CA, Walters SN, Grey ST, Watt SV, Sweet MJ, et al. BAFF and MyD88 signals promote a lupuslike disease independent of T cells. J Exp Med. 2007;204(8):1959–71.PubMedCentralPubMedCrossRef
97.
Groom J, Kalled SL, Cutler AH, Olson C, Woodcock SA, Schneider P, et al. Association of BAFF/BLyS overexpression and altered B cell differentiation with Sjogren’s syndrome. J Clin Invest. 2002;109(1):59–68.PubMedCentralPubMedCrossRef
98.
Carter LM, Isenberg DA, Ehrenstein MR. Elevated serum B-cell activating factor (BAFF/BLyS) is associated with rising anti-dsDNA antibody levels and flare following B-cell depletion therapy in systemic lupus erythematosus. Arthritis Rheum. 2013;. doi:10.​1002/​art.​38074.PubMed
99.
Shinners NP, Carlesso G, Castro I, Hoek KL, Corn RA, Woodland RT, et al. Bruton’s tyrosine kinase mediates NF-kappa B activation and B cell survival by B cell-activating factor receptor of the TNF-R family. J Immunol. 2007;179(6):3872–80.PubMedCrossRef
100.
Mecklenbrauker I, Saijo K, Zheng NY, Leitges M, Tarakhovsky A. Protein kinase Cdelta controls self-antigen-induced B-cell tolerance. Nature. 2002;416(6883):860–5.PubMedCrossRef
101.
Patke A, Mecklenbrauker I, Erdjument-Bromage H, Tempst P, Tarakhovsky A. BAFF controls B cell metabolic fitness through a PKC{beta}- and Akt-dependent mechanism. J Exp Med. 2006;203:2551–62.PubMedCentralPubMedCrossRef
102.
Patke A, Mecklenbrauker I, Tarakhovsky A. Survival signaling in resting B cells. Curr Opin Immunol. 2004;16(2):251–5.PubMedCrossRef
103.
104.
105.
106.
Ettinger R, Browning JL, Michie SA, van Ewijk W, McDevitt HO. Disrupted splenic architecture, but normal lymph node development in mice expressing a soluble lymphotoxin-beta receptor-IgG1 fusion protein. Proc Natl Acad Sci USA. 1996;93(23):13102–7.PubMedCentralPubMedCrossRef
107.
Takemura S, Braun A, Crowson C, Kurtin PJ, Cofield RH, O’Fallon WM, et al. Lymphoid neogenesis in rheumatoid synovitis. J Immunol. 2001;167(2):1072–80.PubMedCrossRef
108.
Motallebzadeh R, Rehakova S, Conlon TM, Win TS, Callaghan CJ, Goddard M, et al. Blocking lymphotoxin signaling abrogates the development of ectopic lymphoid tissue within cardiac allografts and inhibits effector antibody responses. FASEB J. 2012;26(1):51–62. doi:10.​1096/​fj.​11-186973.PubMedCrossRef
109.
Mandik-Nayak L, Huang G, Sheehan KC, Erikson J, Chaplin DD. Signaling through TNF receptor p55 in TNF-alpha-deficient mice alters the CXCL13/CCL19/CCL21 ratio in the spleen and induces maturation and migration of anergic B cells into the B cell follicle. J Immunol. 2001;167(4):1920–8.PubMedCrossRef
110.
Ngo VN, Korner H, Gunn MD, Schmidt KN, Riminton DS, Cooper MD, et al. Lymphotoxin alpha/beta and tumor necrosis factor are required for stromal cell expression of homing chemokines in B and T cell areas of the spleen. J Exp Med. 1999;189(2):403–12.PubMedCentralPubMedCrossRef
111.
Ettinger R, Mebius R, Browning JL, Michie SA, van Tuijl S, Kraal G, et al. Effects of tumor necrosis factor and lymphotoxin on peripheral lymphoid tissue development. Int Immunol. 1998;10(6):727–41.PubMedCrossRef
112.
Harris DP, Haynes L, Sayles PC, Duso DK, Eaton SM, Lepak NM, et al. Reciprocal regulation of polarized cytokine production by effector B and T cells. Nat Immunol. 2000;1(6):475–82. doi:10.​1038/​82717.PubMedCrossRef
113.
Shirota H, Sano K, Hirasawa N, Terui T, Ohuchi K, Hattori T, et al. B cells capturing antigen conjugated with CpG oligodeoxynucleotides induce Th1 cells by elaborating IL-12. J Immunol. 2002;169(2):787–94.PubMedCrossRef
114.
Cariappa A, Boboila C, Moran ST, Liu H, Shi HN, Pillai S. The recirculating B cell pool contains two functionally distinct, long-lived, posttransitional, follicular B cell populations. J Immunol. 2007;179(4):2270–81.PubMedCrossRef
115.
116.
117.
118.
119.
Treml LS, Carlesso G, Hoek KL, Stadanlick JE, Kambayashi T, Bram RJ, et al. TLR stimulation modifies BLyS receptor expression in follicular and marginal zone B cells. J Immunol. 2007;178(12):7531–9.PubMedCrossRef
120.
121.
122.
Kendall PL, Yu G, Woodward EJ, Thomas JW. Tertiary lymphoid structures in the pancreas promote selection of B lymphocytes in autoimmune diabetes. J Immunol. 2007;178(9):5643–51.PubMedCrossRef
123.
124.
125.
Balazs M, Martin F, Zhou T, Kearney J. Blood dendritic cells interact with splenic marginal zone B cells to initiate T-independent immune responses. Immunity. 2002;17(3):341–52.PubMedCrossRef
126.
127.
Dement-Brown J, Newton CS, Ise T, Damdinsuren B, Nagata S, Tolnay M. Fc receptor-like 5 promotes B cell proliferation and drives the development of cells displaying switched isotypes. J Leukoc Biol. 2012;91(1):59–67. doi:10.​1189/​jlb.​0211096.PubMedCrossRef
128.
129.
130.
131.
McCormack R, de Armas LR, Shiratsuchi M, Ramos JE, Podack ER. Inhibition of intracellular bacterial replication in fibroblasts is dependent on the perforin-like protein (perforin-2) encoded by macrophage-expressed gene 1. J Innate Immun. 2013;5(2):185–94. doi:10.​1159/​000345249.PubMedCentralPubMedCrossRef
132.
Khan WN, Nilsson A, Mizoguchi E, Castigli E, Forsell J, Bhan AK, et al. Impaired B cell maturation in mice lacking Bruton’s tyrosine kinase (Btk) and CD40. Int Immunol. 1997;9(3):395–405.PubMedCrossRef
133.
134.
Mizuno T, Rothstein TL. Cutting edge: CD40 engagement eliminates the need for Bruton’s tyrosine kinase in B cell receptor signaling for NF-kappa B. J Immunol. 2003;170(6):2806–10.PubMedCrossRef
135.
Nonoyama S, Tsukada S, Yamadori T, Miyawaki T, Jin YZ, Watanabe C, et al. Functional analysis of peripheral blood B cells in patients with X-linked agammaglobulinemia. J Immunol. 1998;161(8):3925–9.PubMed
136.
137.
Honigberg LA, Smith AM, Sirisawad M, Verner E, Loury D, Chang B et al. The Bruton tyrosine kinase inhibitor PCI-32765 blocks B-cell activation and is efficacious in models of autoimmune disease and B-cell malignancy. Proc Natl Acad Sci USA. 107(29):13075–80. doi:10.​1073/​pnas.​1004594107.
138.
139.
140.
Grimaldi CM, Hicks R, Diamond B. B cell selection and susceptibility to autoimmunity. J Immunol. 2005;174(4):1775–81.PubMedCrossRef
141.
Bohnhorst JO, Bjorgan MB, Thoen JE, Jonsson R, Natvig JB, Thompson KM. Abnormal B cell differentiation in primary Sjogren’s syndrome results in a depressed percentage of circulating memory B cells and elevated levels of soluble CD27 that correlate with Serum IgG concentration. Clin Immunol. 2002;103(1):79–88. doi:10.​1006/​clim 2002.5199.PubMedCrossRef
142.
143.
Carnrot C, Prokopec KE, Rasbo K, Karlsson MC, Kleinau S. Marginal zone B cells are naturally reactive to collagen type II and are involved in the initiation of the immune response in collagen-induced arthritis. Cell Mol Immunol. 2011;8(4):296–304. doi:10.​1038/​cmi.​2011.​2.PubMedCentralPubMedCrossRef
144.
Grammer AC, Slota R, Fischer R, Gur H, Girschick H, Yarboro C, et al. Abnormal germinal center reactions in systemic lupus erythematosus demonstrated by blockade of CD154–CD40 interactions. J Clin Invest. 2003;112(10):1506–20. doi:10.​1172/​JCI19301.PubMedCentralPubMedCrossRef
145.
Takemura S, Klimiuk PA, Braun A, Goronzy JJ, Weyand CM. T cell activation in rheumatoid synovium is B cell dependent. J Immunol. 2001;167(8):4710–8.PubMedCrossRef
146.
147.
Rolf J, Motta V, Duarte N, Lundholm M, Berntman E, Bergman ML, et al. The enlarged population of marginal zone/CD1d(high) B lymphocytes in nonobese diabetic mice maps to diabetes susceptibility region Idd11. J Immunol. 2005;174(8):4821–7.PubMedCrossRef
148.
Marino E, Batten M, Groom J, Walters S, Liuwantara D, Mackay F, et al. Marginal-zone B-cells of nonobese diabetic mice expand with diabetes onset, invade the pancreatic lymph nodes, and present autoantigen to diabetogenic T-cells. Diabetes. 2008;57(2):395–404. doi:10.​2337/​db07-0589.PubMedCrossRef
149.
Aranburu A, Ceccarelli S, Giorda E, Lasorella R, Ballatore G, Carsetti R. TLR ligation triggers somatic hypermutation in transitional B cells inducing the generation of IgM memory B cells. J Immunol. 2010;185(12):7293–301. doi:10.​4049/​jimmunol.​1002722.PubMedCrossRef
150.
151.
152.
153.
154.
155.
156.
157.
Peng SL, Craft J. T cells in murine lupus: propagation and regulation of disease. Mol Biol Rep. 1996;23(3–4):247–51.PubMedCrossRef
158.
159.
Peng SL, Madaio MP, Hayday AC, Craft J. Propagation and regulation of systemic autoimmunity by gammadelta T cells. J Immunol. 1996;157(12):5689–98.PubMed
160.
Shlomchik MJ, Craft JE, Mamula MJ. From T to B and back again: positive feedback in systemic autoimmune disease. Nat Rev Immunol. 2001;1(2):147–53.PubMedCrossRef
161.
Gorelik L, Cutler AH, Thill G, Miklasz SD, Shea DE, Ambrose C, et al. Cutting edge: BAFF regulates CD21/35 and CD23 expression independent of its B cell survival function. J Immunol. 2004;172(2):762–6.PubMedCrossRef
162.
Ng LG, Sutherland AP, Newton R, Qian F, Cachero TG, Scott ML, et al. B cell-activating factor belonging to the TNF family (BAFF)-R is the principal BAFF receptor facilitating BAFF costimulation of circulating T and B cells. J Immunol. 2004;173(2):807–17.PubMedCrossRef
163.
164.
Sasaki Y, Casola S, Kutok JL, Rajewsky K, Schmidt-Supprian M. TNF family member B cell-activating factor (BAFF) receptor-dependent and -independent roles for BAFF in B cell physiology. J Immunol. 2004;173(4):2245–52.PubMedCrossRef
165.
Shulga-Morskaya S, Dobles M, Walsh ME, Ng LG, MacKay F, Rao SP, et al. B cell-activating factor belonging to the TNF family acts through separate receptors to support B cell survival and T cell-independent antibody formation. J Immunol. 2004;173(4):2331–41.PubMedCrossRef
166.
Bouillet P, Purton JF, Godfrey DI, Zhang LC, Coultas L, Puthalakath H, et al. BH3-only Bcl-2 family member Bim is required for apoptosis of autoreactive thymocytes. Nature. 2002;415(6874):922–6.PubMedCrossRef
167.
Bouillet P, Metcalf D, Huang DC, Tarlinton DM, Kay TW, Kontgen F, et al. Proapoptotic Bcl-2 relative Bim required for certain apoptotic responses, leukocyte homeostasis, and to preclude autoimmunity. Science. 1999;286(5445):1735–8.PubMedCrossRef
168.
Davey GM, Kurts C, Miller JF, Bouillet P, Strasser A, Brooks AG, et al. Peripheral deletion of autoreactive CD8 T cells by cross presentation of self-antigen occurs by a Bcl-2-inhibitable pathway mediated by Bim. J Exp Med. 2002;196(7):947–55.PubMedCentralPubMedCrossRef
169.
170.
Craxton A, Draves KE, Gruppi A, Clark EA. BAFF regulates B cell survival by downregulating the BH3-only family member Bim via the ERK pathway. J Exp Med. 2005;202(10):1363–74.PubMedCentralPubMedCrossRef
171.
Khan WN. Regulation of B lymphocyte development and activation by Bruton’s tyrosine kinase. Immunol Res. 2001;23(2–3):147–56.PubMedCrossRef
172.
173.
Kendall PL, Woodward EJ, Hulbert C, Thomas JW. Peritoneal B cells govern the outcome of diabetes in non-obese diabetic mice. Eur J Immunol. 2004;34(9):2387–95.PubMedCrossRef
174.
Schram BR, Tze LE, Ramsey LB, Liu J, Najera L, Vegoe AL, et al. B cell receptor basal signaling regulates antigen-induced Ig light chain rearrangements. J Immunol. 2008;180(7):4728–41.PubMedCrossRef
175.
Sharma S, Orlowski G, Song W. Btk regulates B cell receptor-mediated antigen processing and presentation by controlling actin cytoskeleton dynamics in B cells. J Immunol. 2009;182(1):329–39.PubMedCentralPubMedCrossRef
176.
Abdrakhmanov I, Lodygin D, Geroth P, Arakawa H, Law A, Plachy J, et al. A large database of chicken bursal ESTs as a resource for the analysis of vertebrate gene function. Genome Res. 2000;10(12):2062–9.PubMedCentralPubMedCrossRef
177.
Ait-Azzouzene D, Verkoczy L, Duong B, Skog P, Gavin AL, Nemazee D. Split tolerance in peripheral B cell subsets in mice expressing a low level of Igkappa-reactive ligand. J Immunol. 2006;176(2):939–48.PubMedCrossRef
178.
Thien M, Phan TG, Gardam S, Amesbury M, Basten A, Mackay F, et al. Excess BAFF rescues self-reactive B cells from peripheral deletion and allows them to enter forbidden follicular and marginal zone niches. Immunity. 2004;20(6):785–98.PubMedCrossRef
179.
Jansson L, Holmdahl R. Genes on the X chromosome affect development of collagen-induced arthritis in mice. Clin Exp Immunol. 1993;94(3):459–65.PubMedCentralPubMedCrossRef
180.
Seldin MF, Reeves JP, Scribner CL, Roths JB, Davidson WF, Morse HC 3rd, et al. Effect of xid on autoimmune C3H-gld/gld mice. Cell Immunol. 1987;107(1):249–55.PubMedCrossRef
181.
Steinberg EB, Santoro TJ, Chused TM, Smathers PA, Steinberg AD. Studies of congenic MRL-Ipr/Ipr.xid mice. J Immunol. 1983;131(6):2789–95.PubMed
182.
183.
184.
Honigberg LA, Smith AM, Sirisawad M, Verner E, Loury D, Chang B, et al. The Bruton tyrosine kinase inhibitor PCI-32765 blocks B-cell activation and is efficacious in models of autoimmune disease and B-cell malignancy. Proc Natl Acad Sci USA. 2010;107(29):13075–80. doi:10.​1073/​pnas.​1004594107.PubMedCentralPubMedCrossRef
185.
186.
Gray P, Dunne A, Brikos C, Jefferies CA, Doyle SL, O’Neill LA. MyD88 adapter-like (Mal) is phosphorylated by Bruton’s tyrosine kinase during TLR2 and TLR4 signal transduction. J Biol Chem. 2006;281(15):10489–95.PubMedCrossRef
187.
Jefferies CA, O’Neill LA. Bruton’s tyrosine kinase (Btk)-the critical tyrosine kinase in LPS signalling? Immunol Lett. 2004;92(1–2):15–22.PubMedCrossRef
188.
189.
Tsukada S, Rawlings DJ, Witte ON. Role of Bruton’s tyrosine kinase in immunodeficiency. Curr Opin Immunol. 1994;6:623–30.PubMedCrossRef
190.
Tsukada S, Saffran DC, Rawlings DJ, Parolini O, Allen RC, Klisak I, et al. Deficient expression of a B cell cytoplasmic tyrosine kinase in human X-linked agammaglobulinemia. Cell. 1993;72:279–90.PubMedCrossRef
191.
Vetrie D, Vorchovsky I, Sideras P, Holland J, Davies A, Flinter F, et al. The gene involved in X-linked agammaglobulinemia is a member of the src family of protein-tyrosine kinases. Nature. 1993;361:226–33.PubMedCrossRef
192.
Ochs HD, Smith CI. X-linked agammaglobulinemia. A clinical and molecular analysis. Medicine (Baltimore). 1996;75(6):287–99.CrossRef
193.
Sideras P, Smith CI. Molecular and cellular aspects of X-linked agammaglobulinemia. Adv Immunol. 1995;59:135–223.PubMedCrossRef
194.
Ng YS, Wardemann H, Chelnis J, Cunningham-Rundles C, Meffre E. Bruton’s tyrosine kinase is essential for human B cell tolerance. J Exp Med. 2004;200(7):927–34.PubMedCentralPubMedCrossRef
195.
Broome CV, Breiman RF. Pneumococcal vaccine—past, present, and future. N Engl J Med. 1991;325(21):1506–8.PubMedCrossRef
196.
Conley ME, Cooper MD. Genetic basis of abnormal B cell development. Curr Opin Immunol. 1998;10(4):399–406.PubMedCrossRef
197.
Mond JJ, Lees A, Snapper CM. T cell-independent antigens type 2. Annu Rev Immunol. 1995;13:655–92.PubMedCrossRef
198.
Rawlings DJ. Bruton’s tyrosine kinase controls a sustained calcium signal essential for B lineage development and function [In Process Citation]. Clin Immunol. 1999;91(3):243–53.PubMedCrossRef
199.
Amsbaugh DF, Hansen CT, Prescot B, Stashak PW, Barthold DR, Parker PJ. Genetic control of the antibody response to type III pneumonococcal polysaccharides in mice. I. Evidence that an X-linked gene plays a decisive role in determining responsiveness. J Exp Med. 1972;136:931–6.PubMedCentralPubMedCrossRef
200.
Brunner C, Muller B, Wirth T. Bruton’s tyrosine kinase is involved in innate and adaptive immunity. Histol Histopathol. 2005;20(3):945–55.PubMed
201.
Smith CI, Baskin B, Humire-Greiff P, Zhou JN, Olsson PG, Maniar HS, et al. Expression of Bruton’s agammaglobulinemia tyrosine kinase gene, BTK, is selectively down-regulated in T lymphocytes and plasma cells. J Immunol. 1994;152(2):557–65.PubMed
202.
203.
Mukhopadhyay S, Sahoo PK, George A, Bal V, Rath S, Ravindran B. Delayed clearance of filarial infection and enhanced Th1 immunity due to modulation of macrophage APC functions in xid mice. J Immunol. 1999;163(2):875–83.PubMed
204.
Mukhopadhyay S, George A, Bal V, Ravindran B, Rath S. Bruton’s tyrosine kinase deficiency in macrophages inhibits nitric oxide generation leading to enhancement of IL-12 induction. J Immunol. 1999;163(4):1786–92.PubMed
205.
Davis RE, Ngo VN, Lenz G, Tolar P, Young RM, Romesser PB et al. Chronic active B-cell-receptor signalling in diffuse large B-cell lymphoma. Nature. 463(7277):88–92. doi:10.​1038/​nature08638.
206.
207.
Ponader S, Chen SS, Buggy JJ, Balakrishnan K, Gandhi V, Wierda WG, et al. The Bruton tyrosine kinase inhibitor PCI-32765 thwarts chronic lymphocytic leukemia cell survival and tissue homing in vitro and in vivo. Blood. 2012;119(5):1182–9. doi:10.​1182/​blood-2011-10-386417.PubMedCrossRef
208.
Chang BY, Huang MM, Francesco M, Chen J, Sokolove J, Magadala P, et al. The Bruton tyrosine kinase inhibitor PCI-32765 ameliorates autoimmune arthritis by inhibition of multiple effector cells. Arthritis Res Ther. 2011;13(4):R115. doi:10.​1186/​ar3400.PubMedCentralPubMedCrossRef
209.
Doyle SL, Jefferies CA, O’Neill LA. Bruton’s tyrosine kinase is involved in p65-mediated transactivation and phosphorylation of p65 on serine 536 during NFkappaB activation by lipopolysaccharide. J Biol Chem. 2005;280(25):23496–501.PubMedCrossRef
210.
Jefferies CA, Doyle S, Brunner C, Dunne A, Brint E, Wietek C, et al. Bruton’s tyrosine kinase is a Toll/interleukin-1 receptor domain-binding protein that participates in nuclear factor kappaB activation by Toll-like receptor 4. J Biol Chem. 2003;278(28):26258–64.PubMedCrossRef
Metadaten
Titel
B-lymphocyte tolerance and effector function in immunity and autoimmunity
verfasst von
Wasif N. Khan
Jacqueline A. Wright
Eden Kleiman
Justin C. Boucher
Iris Castro
Emily S. Clark
Publikationsdatum
01.12.2013
Verlag
Springer US
Erschienen in
Immunologic Research / Ausgabe 1-3/2013
Print ISSN: 0257-277X
Elektronische ISSN: 1559-0755
DOI
https://doi.org/10.1007/s12026-013-8466-z

Weitere Artikel der Ausgabe 1-3/2013

Immunologic Research 1-3/2013 Zur Ausgabe

Immunology & Microbiology in Miami

Insights into thymic involution in tumor-bearing mice

Immunology & Microbiology in Miami

Increased number of Langerhans cells in the epidermis of diabetic foot ulcers correlates with healing outcome

Immunology & Microbiology in Miami

Killing machines: three pore-forming proteins of the immune system

Immunology & Microbiology in Miami

Myeloid derived suppressor cells in physiological and pathological conditions: the good, the bad, and the ugly

Immunology & Microbiology in Miami

The immune system and head and neck squamous cell carcinoma: from carcinogenesis to new therapeutic opportunities

Immunology & Microbiology in Miami

The evolving art of hematopoietic stem cell transplantation: translational research in post-transplant immune reconstitution and immunosuppression

Neu im Fachgebiet HNO

Erhebliches Risiko für Kehlkopfkrebs bei mäßiger Dysplasie

29.05.2024 Larynxkarzinom Nachrichten

Fast ein Viertel der Personen mit mäßig dysplastischen Stimmlippenläsionen entwickelt einen Kehlkopftumor. Solche Personen benötigen daher eine besonders enge ärztliche Überwachung.

Hörschwäche erhöht Demenzrisiko unabhängig von Beta-Amyloid

29.05.2024 Hörstörungen Nachrichten

Hört jemand im Alter schlecht, nimmt das Hirn- und Hippocampusvolumen besonders schnell ab, was auch mit einem beschleunigten kognitiven Abbau einhergeht. Und diese Prozesse scheinen sich unabhängig von der Amyloidablagerung zu ereignen.

„Übersichtlicher Wegweiser“: Lauterbachs umstrittener Klinik-Atlas ist online

17.05.2024 Klinik aktuell Nachrichten

Sie sei „ethisch geboten“, meint Gesundheitsminister Karl Lauterbach: mehr Transparenz über die Qualität von Klinikbehandlungen. Um sie abzubilden, lässt er gegen den Widerstand vieler Länder einen virtuellen Klinik-Atlas freischalten.

Betalaktam-Allergie: praxisnahes Vorgehen beim Delabeling

16.05.2024 Pädiatrische Allergologie Nachrichten

Die große Mehrheit der vermeintlichen Penicillinallergien sind keine. Da das „Etikett“ Betalaktam-Allergie oft schon in der Kindheit erworben wird, kann ein frühzeitiges Delabeling lebenslange Vorteile bringen. Ein Team von Pädiaterinnen und Pädiatern aus Kanada stellt vor, wie sie dabei vorgehen.

Update HNO

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert – ganz bequem per eMail.

Newsletter bestellen
Bildnachweise